PMC's new president and CEO said the organization is expanding beyond oncology, engaging with Capitol Hill, and challenging a controversial research grant rule.

NEW YORK – Sangamo Therapeutics has auctioned assets for up to $263.6 million, with PTC Therapeutics winning its gene therapy program in Fabry disease and Eli Lilly its platform technologies and prion ...

NEW YORK – Akeso Bio has launched a Phase II study of a bispecific antibody-drug conjugate in combination with its bispecific antibody ivonescimab for advanced breast cancer. The Zhongshan, ...

The firm reported median overall survival of 26 months in patients with recurrent, high-grade, IDH1-mutant gliomas in a Phase II study.

Revenue from the CAR T-cell therapy for later-line acute lymphoblastic leukemia more than doubled year-over-year.

The investigator-initiated trial comes after Elicio said a Phase II trial of ELI-002 7P in adjuvant pancreatic cancer did not meet its primary endpoint.

The deal centers on Actio's small molecule for KCNT1-related epilepsy. Meanwhile, Actio will spin out a separate company with its other assets.

Researchers explored the effect of germline variants on toxicity in lymphoma patients from two clinical trials of Gilead's Yescarta.

Phase I/II SONIX trial will enroll 10 children with biallelic GJB2 variants to evaluate the gene therapy, called SKY-GJB2.

BeOne has gained exclusive rights to develop and commercialize four Revolution candidates in certain Asian markets.

NEW YORK – The US Food and Drug Administration approved Laboratory Corporation of America's PGDx elio tissue complete as a companion diagnostic for detecting BRAF V600E and BRAF V600K mutations in ...